FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998348531> ?p ?o ?g. }

• W1998348531 endingPage "804" @default.
• W1998348531 startingPage "793" @default.
• W1998348531 abstract "The effect of cholecystokinin peptides on the release of dynorphin B, aspartate, glutamate, dopamine and GABA in the neostriatum and substantia nigra of the rat was investigated using in vivo microdialysis. Sulphated cholecystokinin-8S in the dialysis perfusate (1–100 μM) induced a concentration-dependent increase in extracellular dynorphin B and aspartate levels, both in the neostriatum and substantia nigra. Striatal dopamine levels were only increased by 100 μM of cholecystokinin-8S, while in the substantia nigra they were increased by 10–100 μM of cholecystokinin-8S. Extracellular GABA and glutamate levels were increased following 100 μM of cholecystokinin-8S only. Striatal cholecystokinin-8S administration also produced a significant increase in nigral dynorphin B levels. Local cholecystokinin-4 (100 μM) produced a moderate, but significant, increase of extracellular dynorphin B and aspartate levels in the neostriatum and substantia nigra. No effect was observed on the other neurotransmitters investigated. A 6-hydroxydopamine lesion of the nigrostriatal dopamine pathway did not affect the increases in dynorphin B and aspartate levels produced by local administration of cholecystokinin-8S. Basal extracellular GABA levels were increased significantly in both the neostriatum and substantia nigra ipsilateral to the lesion. Nigral glutamate and aspartate levels were also increased in the lesioned substantia nigra, but in the lesioned neostriatum aspartate levels were decreased. The cholecystokinin-B antagonist L-365,260 (20 mg/kg, s.c.), but not the cholecystokinin-A antagonist L-364,718 (devazepide; 20 mg/kg, s.c.), significantly inhibited the effect of cholecystokinin-8S on striatal dynorphin B and aspartate levels. In the substantia nigra, however, the effect of cholecystokinin-8S on dynorphin B and aspartate levels was inhibited to a similar extent by both L-365,260 and L-364,718. Pretreatment with L-364,718, but not with L-365,260, prevented the increase in nigral dopamine levels produced by nigral cholecystokinin-8S administration. Taken together, these results suggest that cholecystokinin-8S modulates dynorphin B and aspartate release in the neostriatum and substantia nigra of the rat via different receptor mechanisms. In the neostriatum, the effect of cholecystokinin-8S on dynorphin B and aspartate release is mediated via the cholecystokinin-B receptor subtype, while in the substantia nigra, cholecystokinin-8S modulates dynorphin B and aspartate release via both cholecystokinin-A and cholecystokinin-B receptor subtypes. Cholecystokinin-8S modulates dopamine release mainly in the substantia nigra, via the cholecystokinin-A receptor subtype." @default.
• W1998348531 created "2016-06-24" @default.
• W1998348531 creator A5008531602 @default.
• W1998348531 creator A5010768248 @default.
• W1998348531 creator A5034314111 @default.
• W1998348531 creator A5053353441 @default.
• W1998348531 creator A5056066706 @default.
• W1998348531 creator A5057578473 @default.
• W1998348531 creator A5067628389 @default.
• W1998348531 creator A5077494149 @default.
• W1998348531 creator A5078829134 @default.
• W1998348531 creator A5081521018 @default.
• W1998348531 creator A5086473480 @default.
• W1998348531 date "1996-08-01" @default.
• W1998348531 modified "2023-10-15" @default.
• W1998348531 title "Modulation of neurotransmitter release by cholecystokinin in the neostriatum and substantia nigra of the rat: regional and receptor specificity" @default.
• W1998348531 cites W1529961551 @default.
• W1998348531 cites W1546812311 @default.
• W1998348531 cites W1585680102 @default.
• W1998348531 cites W1933591933 @default.
• W1998348531 cites W1965260950 @default.
• W1998348531 cites W1970374596 @default.
• W1998348531 cites W1970403967 @default.
• W1998348531 cites W1976782467 @default.
• W1998348531 cites W1979100850 @default.
• W1998348531 cites W1982450881 @default.
• W1998348531 cites W1983632994 @default.
• W1998348531 cites W1984838114 @default.
• W1998348531 cites W1984945304 @default.
• W1998348531 cites W1985371202 @default.
• W1998348531 cites W1986832734 @default.
• W1998348531 cites W1988247408 @default.
• W1998348531 cites W1988646125 @default.
• W1998348531 cites W1989058665 @default.
• W1998348531 cites W1990096326 @default.
• W1998348531 cites W1990632315 @default.
• W1998348531 cites W1991546506 @default.
• W1998348531 cites W2002134809 @default.
• W1998348531 cites W2003964129 @default.
• W1998348531 cites W2012163398 @default.
• W1998348531 cites W2012219430 @default.
• W1998348531 cites W2022233762 @default.
• W1998348531 cites W2025023187 @default.
• W1998348531 cites W2025586544 @default.
• W1998348531 cites W2027119507 @default.
• W1998348531 cites W2028093765 @default.
• W1998348531 cites W2029015057 @default.
• W1998348531 cites W2030926999 @default.
• W1998348531 cites W2032511112 @default.
• W1998348531 cites W2034228917 @default.
• W1998348531 cites W2036398765 @default.
• W1998348531 cites W2036599008 @default.
• W1998348531 cites W2042307550 @default.
• W1998348531 cites W2045178401 @default.
• W1998348531 cites W2052938351 @default.
• W1998348531 cites W2055994515 @default.
• W1998348531 cites W2058073516 @default.
• W1998348531 cites W2058423921 @default.
• W1998348531 cites W2060584233 @default.
• W1998348531 cites W2066429898 @default.
• W1998348531 cites W2066816450 @default.
• W1998348531 cites W2066852707 @default.
• W1998348531 cites W2066944012 @default.
• W1998348531 cites W2066997249 @default.
• W1998348531 cites W2073414935 @default.
• W1998348531 cites W2073564578 @default.
• W1998348531 cites W2073958527 @default.
• W1998348531 cites W2074636086 @default.
• W1998348531 cites W2074909561 @default.
• W1998348531 cites W2075744470 @default.
• W1998348531 cites W2079416717 @default.
• W1998348531 cites W2080101710 @default.
• W1998348531 cites W2082072550 @default.
• W1998348531 cites W2087867929 @default.
• W1998348531 cites W2088750285 @default.
• W1998348531 cites W2089181902 @default.
• W1998348531 cites W2090430619 @default.
• W1998348531 cites W2095030091 @default.
• W1998348531 cites W2105802588 @default.
• W1998348531 cites W2114116729 @default.
• W1998348531 cites W2122946342 @default.
• W1998348531 cites W2123092430 @default.
• W1998348531 cites W2124793782 @default.
• W1998348531 cites W2140097465 @default.
• W1998348531 cites W2143363653 @default.
• W1998348531 cites W2146276877 @default.
• W1998348531 cites W2275222709 @default.
• W1998348531 cites W4231058111 @default.
• W1998348531 cites W4296759708 @default.
• W1998348531 doi "https://doi.org/10.1016/0306-4522(96)00149-2" @default.
• W1998348531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8884775" @default.
• W1998348531 hasPublicationYear "1996" @default.
• W1998348531 type Work @default.
• W1998348531 sameAs 1998348531 @default.
• W1998348531 citedByCount "49" @default.
• W1998348531 countsByYear W19983485312012 @default.
• W1998348531 countsByYear W19983485312013 @default.
• W1998348531 countsByYear W19983485312015 @default.

• next